Glenmark Pharmaceuticals has informed that, Glenmark Pharmaceuticals Inc., USA (Glenmark), today announced the launch of Axitinib Tablets, 1 mg and 5 mg. This product is an Authorized Generic version of INLYTA®1 (axitinib) tablets. According to IQVIA® sales data for the 12-month period ending September 2026, U.S. annual sales of INLYTA® Tablets were approximately $538.4 million*. The company has attached media release.
The above information is a part of company’s filings submitted to BSE.